A multicentre prospective outcome analysis
A network meta-analysis compared 6 treatments.
QoL analysis from phase 3 HYPO-RT-PC trial.
Routine use of ADT is not recommended for protection against SARS-CoV-2.
Patients on active surveillance should be encouraged to follow a healthy lifestyle.
Study of 2.24 million patients with NSCLC or colon, breast, or prostate cancer.
A new very high-risk group identified.
Secondary analysis of Canadian Cancer Trials Group PR-7 trial.
Findings are from a post hoc analysis of the ARCHES trial.
Focal therapy shows early recovery of urinary and sexual functions.
Phase 3 trial of ADT added to radiotherapy or dose-escalated radiotherapy.
Study reveals an urgent need for consensus on PSA monitoring for this patient group
Approval was based on HERO trial.
Significant OS benefit needs prospective validation.
Cochrane meta-analysis of STAMPEDE and LATITUDE trials.
Final OS analysis of phase 3 PROfound trial.
Findings from a survey of British uro-oncologists.
